Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures

Itasca, IL, US, 12 January 2026 – Biocartis announced today that it has entered into a research collaboration with Mayo Clinic to develop a rapid sample-to-answer test aiming to shorten the time to optimal treatment for breast cancer patients. Mayo Clinic will provide clinical expertise and know-how, archived samples, and pathology services with the goal of accelerating assay development, validation and market access. The test is investigational and not yet available for diagnostic use.

“Optimal care depends on timely access to test results. Rapid local diagnostics can shorten the time to determine patients’ appropriate therapeutic pathway. Our goal is to help make faster testing available to breast cancer patients,” said Matthew P. Goetz, MD, medical oncologist, Mayo Clinic.

“We are excited to collaborate with Mayo Clinic as we seek to bring rapid, high-value testing to breast cancer patients. Our goal is to use this as a first step toward expanding into larger markets including gene signatures, patient monitoring, and early detection. Biocartis has an accomplished history of successful collaborations with academic and pharmaceutical industry partners that have led to the first sample to answer companion diagnostic approved by the U.S. FDA as well as CE-IVD registrations,” said Roger Moody, Chief Executive Officer of Biocartis.